Skip to Content

Uceris Approval History

  • FDA approved: Yes (First approved January 14th, 2013)
  • Brand name: Uceris
  • Generic name: budesonide
  • Company: Santarus, Inc.
  • Treatment for: Ulcerative Colitis

Uceris (budesonide) is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.

Development History and FDA Approval Process for Uceris

Oct  8, 2014Approval FDA Approves Uceris (budesonide) Rectal Foam for Ulcerative Colitis
Jan 15, 2013Approval Santarus Receives FDA Approval of Uceris (budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis
Aug 13, 2012Santarus Announces FDA Extension of Uceris New Drug Application Target Action Date to January 16, 2013
Feb 15, 2012Santarus Announces FDA Acceptance of Uceris New Drug Application for Induction of Remission of Active Ulcerative Colitis
Dec 20, 2011Santarus Submits New Drug Application to FDA for Uceris (budesonide) Tablets

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.